艾滋病支出趋势：持续的艾滋病患者护理与创新

Sustaining Patient Care and Innovation in HIV Introduction Driven by robust scientific research and innovation, collaboration among globalhealth organizations, and substantial dedicated funding, the treatment andprevention of human immunodeficiency virus (HIV) have seen extraordinaryprogress in the last two decades. In most cases, HIV infection can be managed The study was produced independently by theIQVIA Institute for Human Data Science. This reportwas commissioned and funded by Gilead Sciences This report highlights some of the main unmet needsin HIV and challenges with developing treatments toaddress them. It also captures the dynamics aroundresearch and development (R&D) along with spendingand healthcare policy which can have an impact on the Find Out More If you wish to receive future reports from the IQVIAInstitute for Human Data Science or join our mailing list, MURRAY AITKENExecutive Director REFERENCING THIS REPORTPlease use this format when referencing content from this report:Source: IQVIA Institute for Human Data Science. HIV Spending Trends: Sustaining Patient Care and Innovation in HIV. November 2025. ©2025 IQVIA and its affiliates. All reproduction rights, quotations, broadcasting, publications reserved. No part of this publication may be reproduced ortransmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without Table of Contents Overview2Progress in HIV treatment and prevention and remaining unmet needs4Trends in HIV R&D, spending, and policies7Discussion and call to action13Definitions14References15About the authors19About the Institute21 OverviewOverview Treatments for human immunodeficiency virus (HIV)have advanced substantially over the past four decadeswith the introduction of highly effective antiretroviraltherapies (ART) and pre-exposure prophylaxis (PrEP)for prevention of new infections. Globally, an estimated Inadequate adherence to ART heightens the risk of drugresistance, a challenge prevalent not only in low- andmiddle-income countries but also high income countries.This situation necessitates treatment options that While preventing and addressing drug resistance iscritical, the broader vision for combating HIV includesthe development of an effective vaccine and a scalablecure. Achieving a cure is a complex challenge requiring HIV incidence trends reveal persistent health andsocioeconomic inequities, with barriers like fragmentedhealthcare systems, stigma, and discriminationhindering access to prevention and treatment. Addressing the unmet needs of diverse and vulnerablepopulations, mitigating the risk of drug resistance, andpursuing the ultimate goals of ending the HIV epidemicare all dependent on sustained funding for HIV along Bit volorentis rero bernati occustexcea pra doluptatur alita quiamet es volectorere vel idus rem sitex eturiati berum atiis experoexpe pro quunt moluptat quique none cuscien ihilia aut quamfaccae duciaecae dollut rem.Globally, an estimated 40.8 millionpeople were living with HIV in 2024,with approximately 31.6 millionaccessing life-saving antiretroviraltherapies (ART). Given the research, funding and policy space for HIV,the long-term benefits of sustained investment in HIVtreatment and prevention requires further discussionacross policymakers and all HIV related stakeholders.A few key areas for dialogue amongst stakeholders Global spending at manufacturer list price level on HIVmedication has been increasing over the past decadewith spending in the U.S. driving much of the growth. Atthe same time, HIV medication spending in Europe hasbeen flat. Across a selected set of European countries Overall pricing and access policies in European countriesare evolving as well. Given the nature of remainingunmet needs in HIV, a supportive and sustainablefunding system for such treatments is required.However, the evolving policy dynamics may createfurther challenges for the appropriate assessmentof the value of such treatments. For example, health Given the research, funding andpolicy space for HIV, the long-termbenefits of sustained investmentin HIV treatment and prevention Progress in HIV treatment and prevention and remaining Medicines for human immunodeficiency virus (HIV)have advanced substantially over the past four decadeswith the introduction of highly effective antiretroviraltherapies (ART) and pre-exposure prophylaxis (PrEP). sharing knowledge, and scaling up treatment programsworldwide, ensuring that innovations in HIV treatment While significant progress has been made in HIVtreatment, several areas of unmet need remain that UNMET NEED: ENSURING APPROPRIATE TREATMENTFOR EVOLVING NEEDS OF PEOPLE LIVING WITH HIV HIV incidence trends continue to highlight starkdifferences in status.3,4Barriers such as siloedhealthcare, lack of care coordination, stigma, anddiscrimination persistently hinder access to bothprevention and treatment.3,5These